Journals / Ankara Eğitim ve Araştırma Hastanesi Tıp Dergisi / 2019 / Cilt: 52 - Sayı: 2

Monocyte to HDL-Cholesterol Ratio in Male with Hypogonadotropic Hypogonadism

Erkek İdiopatik Hipogonadotropik Hipogonadizmli Hastalarda Monosit/ HDL oranı

Pages
128–132
Publication Date
2019-07-31
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: MHR has been shown to be an indicator of cardiovascular risk in previous studies but we could not detect an increased MHR value in patients with IHH In this study.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: Previous studies have shown that idiopatic hypogonadotropic hypogonadism (IHH) patients with low testosterone levels lead to an impaired glucose metabolism, and an increased cardiovascular risk.
📊
Key Findings & Data:Material and Methods: This study includes 31 men with IHH without previous treatment for the disease and 44 healthy men.
💡
Conclusion & Impact:Conclusion: MHR has been shown to be an indicator of cardiovascular risk in previous studies but we could not detect an increased MHR value in patients with IHH In this study.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Monosit · HDL kolesterol · inflamasyon

Abstract

Purpose: Previous studies have shown that idiopatic hypogonadotropic hypogonadism (IHH) patients with low testosterone levels lead to an impaired glucose metabolism, and an increased cardiovascular risk. Monocyte to high-density lipoprotein cholesterol (HDL-C) ratio (MHR) also has been shown to be an indicator of inflammation and cardiovascular risk. The purpose of the present study is to investigate MHR in the male with IHH. Material and Methods: This study includes 31 men with IHH without previous treatment for the disease and 44 healthy men. The blood sampling, anthropometric measures, and physical examination were undertaken by all the participants. Results: Mean ages of the IHH patients and the healty controls were 22.5±7.2 years vs. 22.9±6.4 years. There was no statistically significant difference between the patients and controls in terms of the mean HDL-C, mean monocyte count, and mean MHR. The MHR also was not correlated with the other hematological parameters, inflammatory parameters, and the total testosterone level. Conclusion: MHR has been shown to be an indicator of cardiovascular risk in previous studies but we could not detect an increased MHR value in patients with IHH In this study.

Özet

Amaç: Önceki çalışmalar, düşük testosteron düzeylerine sahip idiopatik hipogonadotropik hipogonadizm (İHH) hastalarında bozulmuş glukoz metabolizmasına ve artmış kardiyovasküler riske yatkınlık olduğunu göstermiştir. Monosit/yüksek yoğunluklu lipoprotein kolesterol (HDL-C) oranı (MHR) de inflamasyon ve kardiyovasküler risk göstergesi olarak gösterilmiştir. Bu çalışmanın amacı, İHH tanılı erkek hastalarda MHR'yi araştırmaktır. Gereç ve Yöntemler: Bu çalışmaya daha önce tedavi almamış İHH tanısı olan 31 erkek hasta ve sağlıklı 44 erkek hasta dahil edildi. Tüm katılımcıların kan örneklemesi, antropometrik ölçümleri ve fizik muayeneleri yapıldı. Bulgular: İHH hastalarının yaş ortalaması 22,5±7,2 yıl ve sağlıklı kontrollerin yaş ortalaması ise 22,9±6,4 yıl idi. Hastalar ve kontroller arasında ortalama HDL-kolesterol, ortalama monosit sayısı ve ortalama MHR açısından istatistiksel olarak anlamlı bir fark yoktu. MHR ayrıca diğer hematolojik parametreler, enflamatuar parametreler ve toplam testosteron seviyesi ile korele değildi. Sonuçlar: Önceki çalışmalarda MHR'nin kardiyovasküler riskin bir göstergesi olduğu gösterilmiştir, ancak bu çalışmada İHH hastalarında artmış bir MHR değeri tespit edemedik.

🔖

Cite This Article

ÇADIRCI, K., OĞUZ, İ., USTA, T., KESKİN, H., ÇARLIOĞLU, A., ARIKAN, Ş. (2019). Monocyte to HDL-Cholesterol Ratio in Male with Hypogonadotropic Hypogonadism. Ankara Eğitim ve Araştırma Hastanesi Tıp Dergisi, Cilt: 52 - Sayı: 2, 128–132. https://ajindex.com/articles/712735

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Fraietta R, Zylberstejn DS, Esteves SC. Hypogonadotropic hypogonadism revisited. Clinics (Sao Paulo). 2013;68 Suppl 1:81-8
  2. Tang RY, Chen R, Ma M, Lin SQ, Zhang YW, Wang YP. Clinical characteristics of 138 Chinese female patients with idiopathic hypogonadotropic hypogonadism. Endocr Connect. 2017 Nov;6(8):800-10. doi: 10.1530/EC-17-0251. Epub 2017 Oct 10
  3. Özbey İ. Treatment of hypogonadotropic hypogonadism. Turkiye Klinikleri J Urology-Special Topics. 2017;10(1):19-27 4. Maggio M, Basaria S, Ble A, et al. Correlation between testosterone and the inflammatory marker soluble interleukin-6 receptor in older men. J Clin Endocrinol Metab. 2006 Jan;91(1):345-7. Epub 2005 Nov 1
  4. Nettleship JE, Pugh PJ, Channer KS, Jones T, Jones RD. Inverse relationship between serum levels of interleukin-1ß and testosterone in men with stable coronary artery disease. Horm Metab Res.2007; 39(5), 366–71. DOI: 10.1055/s-2007-976543 6. Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation. 2004 Jun 1;109(21 Suppl 1):II2-10
  5. World Health Organization. Cardiovascular Disease (CVDs). https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-%28cvds%29 accessed date: 01.04.2019 8. Doğan BA, Karakılıç E, Tuna MM, Arduç A, Berker D, Güler S. Effect of androgen replacement therapy on atherosclerotic risk markers in young-to-middle-aged men with idiopathic hypogonadotropic hypogonadism. Clin Endocrinol (Oxf) 2015;82:422–28
  6. Kalinchenko SY, Tishova YA, Mskhalaya GJ, Gooren LJ, Giltay EJ, Saad F. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study. Clin Endocrinol (Oxf). 2010 Nov;73(5):602-12. doi: 10.1111/j.1365-2265.2010.03845.x
  7. Parihar A, Eubank TD, Doseff AI. Monocytes and macrophages regulate immunity through dynamic networks of survival and cell deathJ Innate Immun. 2010;2(3):204-15. doi: 10.1159/000296507. Epub 2010 Mar 16
  8. Kratofil RM, Kubes P, Deniset JF. Monocyte conversion during inflammation and injury. Arterioscler Thromb Vasc Biol. 2017 Jan;37(1):35-42. doi: 10.1161/ATVBAHA.116.308198. Epub 2016 Oct 20
  9. Leentjens J, Bekkering S, Joosten LAB, Netea MG, Burgner DP, Riksen NP. Trained innate immunity as a novel mechanism linking infection and the development of atherosclerosis. Circ Res. 2018 Mar 2;122(5):664-69. doi: 10.1161 / CIRCRESAHA. 117.312465. Epub 2018 Jan 24 1